prostate cancer

[Nature Communications] Scientists found that intermittent but not daily dosing of a PI3Kα/β/δ inhibitor, BAY1082439, on Pten-null prostate cancer models could overcome immune checkpoint therapy resistance and unleash CD8+ T cell-dependent anti-tumor immunity in vivo.

[Molecular Cancer Research] The authors demonstrated that MUC1-C drove global changes in chromatin architecture in the dedifferentiation of CRPC and triple-negative breast cancer cells.

[Molecular Cancer therapeutics] Scientists performed transcriptomic analysis and confirmed that fractionated ionizing radiation (FIR)-induced neuroendocrine (NE)-like cells share some features of clinical NE prostate cancer, suggesting that FIR-induced NE differentiation represents a clinically-relevant model.

[Journal of Materials Chemistry B] The authors found that the inhibition of Hsp90 could inhibit the overexpression of its client proteins such as anti-apoptotic proteins and androgen receptor, thereby improving the efficacy of photodynamic therapy and inducing prostate cancer cell apoptosis.

[Journal of Cancer Research and Clinical Oncology] Researchers investigated whether acquired resistance against ionizing radiation or docetaxel chemotherapy—two commonly applied treatment modalities in prostate cancer—influences the cisplatin tolerance in metastatic CRPC cell line models.

[Journal of Experimental & Clinical Cancer Research] Using lentiviral stable miRNA transfection together with cell biology functional assays and gene expression/target analysis, scientists investigated the interaction between MALAT1 and miR-423-5p, defined as a target with in silico prediction analysis, in prostate cancer.